EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment

Farooqahmed S Kittur, Chiu-Yueh Hung, P Andy Li, David C Sane, Jiahua Xie

Pharmaceuticals · 18.04.2023 · 16 (4) · 610

DOI: 10.3390/ph16040610 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 18.04.2023. Verfasst von Farooqahmed S Kittur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Biomanufacturing Research Institute & Technology Enterprise, North Carolina Central University, Durham, NC 277…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R) injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin (rhuEPOM) has been demonstrated to have excellent neuroprotective functions in preclinical studies, but its neuroprotective properties could not be consistently translated in clinical trials. The clinical failure of rhuEPOM was thought to be mainly due to its erythropoietic activity-associated side effects. To exploit its tissue-protective property, various EPO derivatives with tissue-protective function only have been developed. Among them, asialo-rhuEPO, lacking terminal sialic acid residues, was shown to be neuroprotective but non-erythropoietic. Asialo-rhuEPO can be prepared by enzymatic removal of sialic acid residues from rhuEPOM (asialo-rhuEPOE) or by expressing human EPO gene in glycoengineered transgenic plants (asialo-rhuEPOP). Both types of asialo-rhuEPO, like rhuEPOM, displayed excellent neuroprotective effects by regulating multiple cellular pathways in cerebral I/R animal models. In this review, we describe the structure and properties of EPO and asialo-rhuEPO, summarize the progress on neuroprotective studies of asialo-rhuEPO and rhuEPOM, discuss potential reasons for the clinical failure of rhuEPOM with acute ischemic stroke patients, and advocate future studies needed to develop asialo-rhuEPO as a multimodal neuroprotectant for ischemic stroke treatment.

Schlagwörter

Stichwörter der Autor:innen

asialo-erythropoietincerebral ischemia and reperfusionclinical trialerythropoietinerythropoietin receptorhematopoietic activitymultimodal neuroprotectantnon-erythropoiesispreclinical study

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Biomanufacturing Research Institute & Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA.
  • Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, VA 24014, USA.

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Kittur, F. S., Hung, C. Y., Li, P. A., Sane, D. C., & Xie, J. (2023). Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment. Pharmaceuticals, 16(4), 610. https://doi.org/10.3390/ph16040610

Vancouver

Kittur FS, Hung CY, Li PA, Sane DC, Xie J. Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment. Pharmaceuticals. 2023;16(4):610. doi:10.3390/ph16040610

BibTeX
@article{Kittur2023,
  author = {Kittur, Farooqahmed S and Hung, Chiu-Yueh and Li, P Andy and Sane, David C and Xie, Jiahua},
  title = {Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {4},
  pages = {610},
  doi = {10.3390/ph16040610}
}
Kostenlos starten →